Investors have welcomed new data from Australian biopharmaceutical company Immutep from a trial involving its eftilagimod alpha in combination with MSD's PBS-listed immunotherapy KEYTRUDA (pembrolizumab). …
Latest Video
New Stories
-
Australia can increase prices in response to pressure, as it did just 36 months ago for 950 medicines
December 2, 2025 - - Latest News -
CLINUVEL advances second therapy toward market with planned 2026 European filing
December 2, 2025 - - Australian Biotech -
Burnt-Out Australians rush to health appointments as year-end pressure peaks
December 2, 2025 - - Other Health -
First patient successfully dosed in TRP-8803 trial to treat binge eating disorder
December 2, 2025 - - Australian Biotech -
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 - - Australian Biotech -
New national push to close Australia’s cardiovascular data gap
December 2, 2025 - - Latest News -
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News